Boehringer Ingelheim has signed a commercial supply agreement for biotechnology firm BeiGene’s tislelizumab. Tislelizumab is an investigational humanised monoclonal antibody being developed to bind to the PD-1 receptor known to down-regulate the immune system through […]
Specifically, the drug’s label allows for its use in adults inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists. AZ says Fasenra (benralizumab) – a monoclonal antibody that recruits natural killer cells to deplete eosinophils […]
The adult heart failure trial will be conducted at Imperial College London’s Royal Brompton, UK, and is expected to complete in 2020, which means that the therapy – Celixir’s lead investigational cardiac regenerative medicine – […]
On January 7th 2018, Celgene and Impact Biomedicines announced the signing of a definitive agreement in which Celgene will acquire lmpact Biomedicines, which is developing its sole clinical candidate, fedratinib, a highly selective JAK2 kinase […]
s part of the new structure, Sanofi will receive global development and commercialisation rights to an investigational RNAi therapeutic fitusiran currently being developed to treat haemophilia A and B. When approved, fitusiran will be commercialised […]